Related Experiment Video
Updated: May 27, 2026
07:42
Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
Published on: April 26, 2012
[Oxaliplatin-associated neurotoxicity in clinical practice]
P Mas Morey1, M Cholvi Llovell, M Nigorra Caro
1Servicio de Farmacia, Hospital Son Llàtzer, Palma de Mallorca, Illes Balears, España. p_mas_morey@hotmail.com
Summary
Oxaliplatin-based chemotherapy frequently causes neurotoxicity in colorectal cancer patients, often requiring treatment modification. Further research is needed to develop protective strategies and improve patient quality of life.
Area of Science:
- Oncology
- Neuroscience
- Clinical Pharmacology
Background:
- Oxaliplatin is a key chemotherapeutic agent for colorectal cancer.
- Neurotoxicity is a common dose-limiting side effect of oxaliplatin.
- Effective management strategies for oxaliplatin-induced neurotoxicity are crucial.
Purpose of the Study:
- To assess the incidence and severity of oxaliplatin-associated neurotoxicity in clinical practice.
- To evaluate the clinical management of oxaliplatin-induced neurotoxicity.
- To identify factors associated with neurotoxicity development.
Main Methods:
- Retrospective observational study of 64 colorectal cancer patients treated with oxaliplatin.
- Data collected from hospital prescription programs and digital clinical histories.
- Analysis of patient characteristics, chemotherapy regimens, neurotoxicity occurrence, and management strategies.
Main Results:
- Neurotoxicity occurred in 65.6% of patients, predominantly mild to moderate.
- Oxaliplatin prescription modification was necessary in approximately one-third of affected patients.
- A significant correlation was found between cumulative oxaliplatin dose and neurotoxicity (P=.0004).
Conclusions:
- The observed rates of oxaliplatin neurotoxicity align with existing literature.
- The frequency of treatment modifications highlights the clinical impact of neurotoxicity.
- Development of effective neurological protection strategies is essential for patient safety and quality of life.
Related Concept Videos
01:24Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
01:24Drug Toxicity: Dose-Dependent Reactions
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
01:00Drug Toxicity: Overview
Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...
01:26Anticholinesterase Agents: Poisoning and Treatment
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...